This site is intended for healthcare professionals

Artesunate Amivas granted EU approval for treatment of severe malaria.

Read time: 1 mins
Published:1st Dec 2021
Amivas Ireland Ltd., specialists in treatments for rare and neglected tropical diseases, including severe malaria, has announced the European Commission has granted approval for the Company to commercialize its lead product, Artesunate Amivas (artesunate), in EU/EEA.

The approval was based on the recent recommendation by the Committee for Medicinal Products for Human Use (CHMP) to grant marketing authorization for the medicinal product Artesunate Amivas (artesunate), intended for initial treatment of severe malaria in adults and children. Artesunate Amivas will be available as 110 mg powder and solvent for solution for injection.

Condition: Malaria
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.